Name: APG-2575 (lisaftoclax)
Brand: Selleck Chemicals
SKU: S9970
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: S997001 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.55%

Cited in Nature Medicine for its top-tier quality
COA
SDS/MSDS
Datasheet

99.55

Related Targets	Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras KRas
Other Bcl-2 Inhibitors	Navitoclax (ABT-263) S63845 ABT-737 Obatoclax Mesylate (GX15-070) A-1331852 A-1210477 TW-37 A-1155463 Dihydrochloride AZD5991 UMI-77

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (113.32 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.650mg/ml (1.87mM)	Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.800mg/ml (0.91mM)	Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	882.43	Formula	C₄₅H₄₈ClN₇O₈S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2180923-05-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Bcl-2 2 nM Bcl-xl 5.9 nM
References	[1] https://www.freepatentsonline.com/WO2018027097A1.html

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07686965	NOT_YET_RECRUITING	Acute Myeloid Leukemia (AML); Maintenance Treatment; Hematopoetic Stem Cell Transplantation	Institute of Hematology & Blood Diseases Hospital, China	2026-08-10	PHASE3
NCT07651176	ENROLLING_BY_INVITATION	Acute Myeloid Leukemia; Lisaftoclax	First Affiliated Hospital of Zhejiang University	2026-03-01	PHASE2; PHASE3
NCT07651163	ENROLLING_BY_INVITATION	Acute Myeloid Leukemia (AML); Lisaftoclax	First Affiliated Hospital of Zhejiang University	2026-03-01	PHASE2; PHASE3
NCT07795099	NOT_YET_RECRUITING	Acute Lymphoblastic Leukemia	LanZhou University	2026-08
NCT06641414	RECRUITING	Higher-risk Myelodysplastic Syndrome	Ascentage Pharma Group Inc.	2025-01-22	PHASE3
NCT07398638	NOT_YET_RECRUITING	Diffuse Large B Cell Lymphoma (DLBCL)	Sun Yat-sen University	2026-02-28	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

APG-2575 (lisaftoclax) Bcl-2 inhibitor

Chemical Structure

Molecular Weight: 882.43